Investigation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin levels in multiple sclerosis patients

Sevil Kurban¹, Zehra Akpinar², Idris Mehmetoglu¹

University of Selcuk, Meram Faculty of Medicine, Departments of ¹Biochemistry, ²Neurology, Konya, TURKEY

ABSTRACT

Aim: The aim of this study was to investigate the osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) levels and their correlation with bone mineral density (BMD) and levels of other bone turnover parameters such as serum osteocalcin, parathyroid hormone (PTH), calcium, bone alkaline phosphatase (bALP) and urinary deoxypyridinoline (DPD) in patients with multiple sclerosis (MS).

Methods: Forty six MS patients (30F, 16M, 33.48 ± 9.57 years old) and 24 healthy controls (14F, 10M, 33.04 ± 7.97 years old) were included in the study. Serum OPG, RANKL, bALP, osteocalcin, PTH, calcium, urinary DPD levels of all subjects, and BMD of 29 patients and all control subjects were measured. Osteoprotegerin and RANKL levels, bALP, osteocalcin and PTH levels, and urinary DPD levels were measured by ELISA method, chemiluminescent method, and HPLC technique. The BMD was measured by dual-X-ray absorptiometry.

Results: Serum OPG (p<0.01), RANKL (p<0.01), bALP (p<0.05), PTH (p<0.01) and calcium (p<0.05) levels were significantly higher in MS patients than in controls. There was no significant difference between serum osteocalcin, urinary DPD levels and BMD measures of the groups.

Conclusion: Increased RANKL levels associated with osteoclastogenesis suggests a tendency towards osteoporosis in MS patients. However, no significant change in BMD levels of the subjects shows that the effect of RANKL is compensated by increased OPG levels. OPG and RANKL levels are involved in the pathogenesis and regulation of bone turnover and thus, circulating levels of them may be useful markers to assess bone turnover and to develop new approaches in MS.

Conflict of Interest: The authors declare no conflict of interest.

Key words: Bone mineral density, Multiple sclerosis, Osteoporosis, Osteoprotegerin, Receptor activator of NF-kappaB ligand

ÖZET

Amaç: Bu çalışmanın amacı multiple skleroz (MS) hastalarında osteoprotegerin (OPG) ve nükleer faktör kappaB ligand reseptör aktivatörü (RANKL) seviyelerini ve onların kemik mineral dantesi (KMD) ve serum osteokalsin, parathormon (PTH), kalsiyum, kemik alkan fosfatazi (kALP) ve idrar deoksipiridinolin (DPD) gibi diğer kemik turnover parametrelerinin seviyeleri ile ilişkisini araştırmaktır.

Yöntemler: Çalışmada 46 MS hastası (30K, 16E, 33,48 ± 9,57 yaş) ve 24 sağlıklı kontrol (14K, 10E, 33,04 ± 7,97 yaş) dahil edildi. Tüm vakaların serum OGP, RANKL, kALP, osteokalsin, PTH, kalsiyum, idrar DPD seviyeleri ile 29 hastanın ve tüm kontrol vakalarının KMD ölçüldü. Osteoprotegerin ve RANKL seviyeleri ELISA metodu, kALP, osteokalsin ve PTH seviyeleri kemilüminesans metod ve idrar DPD seviyeleri HPLC tekniği kullanılarak ölçüldü. Kemik mineral dantesi dual-X-ray absorptiometri ile ölçüldü.

Bulgular: MS hastalarının serum OPG (p<0.01), RANKL (p<0.01), kALP (p<0.05), PTH (p<0.01) ve kalsiyum (p<0.05) seviyeleri sağlıklı kontrollerden anlamlı olarak yüksek bulundu. Grupların serum osteokalsin, idrar DPD seviyeleri ve KMD ölçümleri arasında önemli farklılık yoktu.

Sonuçlar: Çalışma sonuçunda osteoklastogenesis ile ilişkil RANKL seviyelerinin MS hastalarında artmış bulunması, osteoporozu eğilim olduğu gösterildi. Fakat olguların KMD değerlerinde değişiklik olmaması RANKL’nin etkisinin OPG seviyelerinde artma ile kompanseli edildiği göstermektedir. Sonuç olarak, kemik turnover patogenezinde ve regulasyonunda rol oynayan OPG ve RANKL’nin ulaşabdaki seviyeler MS’deki kemik turnoveri değerlendirmede faydali bir marker olabilir ve tedavide yeni yaklaşımlar geliştirilmesine katkı sağlayabilir.

Çiçek Çatışması: Yazarların mevcut olan konuya ilgili herhangi bir çatışma bulunmamaktadır.

Anahtar Kelimeler: Kemik mineral dantesi, Multiple skleroz, Osteoporoz, Osteoprotegerin, NF-kappaB ligand reseptör aktivatörü
Introduction

Multiple sclerosis (MS) is a progressive and inflammatory autoimmune disorder of the central nervous system that causes early disability in young adults [1]. Multiple sclerosis patients are at greater risk of osteoporosis and pathological fractures, the underlying mechanism of which is uncertain [2-7]. However, it has been reported that acute and long-term glucocorticoid use, early decrease of physical activity, motor disturbances caused by progressive pyramidal deficit and cerebellar dysfunction accompanied by ataxia with frequent falls, possible skeletal muscle atrophy and the activation of immunoregulatory mechanisms modulating cytokine pathways are likely to be determinants [3-5]. Also, MS patients have a high risk of low bone mineral density (BMD). Reduced BMD in MS patients is associated with high level of Expanded Disability Status Scale (EDSS) score, vitamin D deficiency and disease duration [2-7].

Bones are constantly remodelled through the synthesis of bone matrix by osteoblasts and the resorption of bone by osteoclasts. Thus, bone remodeling depends on a delicate balance between bone formation and bone resorption. Perturbations in inflammatory cytokines and hormones such as interleukin (IL)-1, IL-4, IL-6, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor (TNF)-α, TNF-β and colony stimulating factor (CSF)-1, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 and glucocorticoids cause an imbalance between osteoclast and osteoblast activities and can result in skeletal abnormalities such as osteoporosis and osteopetrosis [8-11].

The osteoprotegerin (OPG)/receptor activator of nuclear factor kappaB (RANK)/RANK ligand (RANKL) system, solved a long standing unresolved question in bone biology, namely the precise mechanisms by which preosteoblastic/stromal cells controlled osteoclast development. The identification of the OPG/RANK/RANKL system as the dominant, final mediator of osteoclastogenesis represents a major advance in bone biology. Osteoprotegerin, a soluble protein member of the TNF receptor family, and its ligand, RANKL, are recently identified cytokines that regulate osteoclastogenesis [9, 11-14]. They are essential paracrine mediators of bone metabolism and immune functions and have been clearly implicated in various skeletal and immune disorders and diseases at the interface between bone metabolism and the immune system [9, 10, 12]. Ligation of RANKL to its cognate receptor RANK, which is expressed by osteoclasts and their precursors, promotes osteoclast formation, fusion, differentiation, activation and survival, leading to enhanced bone resorption and bone loss. Osteoprotegerin binding to RANKL inhibits the osteoclastogenic interaction between RANKL and RANK and prevents its function. The secretion of OPG and RANKL from osteoblasts and stromal cells is regulated by numerous hormones, peptides and cytokines [9, 11-14]. Although OPG mRNA is not restricted to bone and is expressed in a number of tissues, RANKL is produced by osteoblastic lineage cells [9, 11-14].

The balance between OPG/RANK/RANKL signaling and the levels of biologically active OPG and RANKL regulate development and activation of osteoclasts and bone metabolism. Consequently, excess RANKL increases bone resorption, whereas excess OPG inhibits bone turnover by inhibiting osteoclast maturation and osteoclast activation [11-15]. Abnormalities of the OPG/RANK/RANKL system have been reported in various immune-mediated human diseases, such as rheumatoid arthritis [16], osteoarthritis [16], coronary artery disease [17], peripheral vascular disease [17], cancers which damage the human skeleton [18] and MS disease [19]. Further understanding of this system may lead to new therapeutic approaches in treating cancers that develop in the skeleton and postmenopausal osteoporosis [18]. Bone alkaline phosphatase (bALP) and osteocalcin are secreted by osteoblasts and thought to play a role in bone formation. Calcium (Ca) plays an important role in building stronger, denser bones early in life and keeping bones strong and healthy later in life. Long-term Ca deficiency can lead to osteoporosis, in which the bone deteriorates and there is an increased risk of fractures. While a lifelong deficit can affect bone and tooth formation, over-retention can cause hypercalcemia. Urinary deoxypyridinoline (DPD) is a degradation product of type I collagen and is a bone degradation marker [20].

Emerging data suggest a significant increase in the prevalence of osteoporosis and high risk of low BMD in MS patients compared to age-matched controls [3-7], but the molecular mechanism of osteoporosis in MS patients is not known and it may be due to increased osteoclast activity. Since the OPG/RANK/RANKL system appears to be the most relevant therapeutic target for all bone diseases, we aimed to investigate the serum OPG and RANKL levels and their correlation with BMD and levels of other bone turnover parameters such as serum osteocalcin, PTH, Ca, bALP and urinary DPD in patients with MS.

Materials and Methods

Patients

Forty six MS patients (30F, 16M) aged 20 to 53 years (mean 33.48 ± 9.57 years) and 24 healthy controls (14F, 10M) aged 21 to 52 years (mean 33.04 ± 7.97 years) were enrolled in the study. The patients were diagnosed as relapsing-remitting MS according to McDonald’s criteria [21] and followed up by the Department of Neurology, Meram Medical Faculty, Selcuk University, Konya, Turkey. The functional status of MS patients was evaluated by using the EDSS [22], performed by a single neurologist, who was blind to the OPG and RANKL levels and BMD status. None of the patients had formerly diagnosed with any bone disease or disease that can affect...
bone metabolism other than osteoporosis, neither were on any drug therapy affecting bone metabolism. Any MS patients who have a history of treatment for osteoporosis were also excluded from the study. Subjects with inflammatory diseases, any metabolic bone diseases or who were on treatment with any of the drugs that may affect bone metabolism were not included as controls.

The study protocol was approved by the Ethics Committee of Meram Medical School, University of Selcuk, Konya, Turkey (Date: 27 February 2007, number: 280-1255). All subjects were informed with the details of the study and the written consent of each subject was received.

**Measurement of Biochemical Parameters**

Blood samples were collected from each participant after an overnight (10 to 12h) fasting and sera were separated. Serum intact PTH, bALP, osteocalcin and Ca levels were studied immediately and serum samples were stored at −80°C until the day of RANKL and OPG analysis. Serum bALP (Ostase, Access, Beckman Coulter, Fullerton, CA, USA), osteocalcin and intact PTH (Immulite Diagnostic Products Co., Los Angeles, CA, USA) levels were measured by commercially available chemiluminescent immunoassays. Reference ranges of PTH, bALP, osteocalcin and Ca were 11-67 pg/mL, 5.8-17.90 µg/L, 2-21 ng/mL and 8.6-10.3 mg/dL, respectively. Serum Ca and urinary creatinine levels were measured by routine methods (Beckman Coulter, Fullerton, CA, U.S.A.). Urinary DPD levels (adjusted for creatinine excretion, normal range, 6-26 pmol/µmol creatinine) in first morning urine specimens were analyzed using Chromsystems reagent kit for high-performance liquid chromatography (HPLC) technique on an Agilent 1100 series fluorescence detector on the same day.

The intra- and inter-assay coefficient of variations (CV) (%) of the parameters were as follows: PTH 4.7% and 6.8%, bALP 2.6% and 4.29%, osteocalcin 2.52% and 2.65%, Ca 1.33% and 1.64% and DPD 5.4% and 8.2%, respectively.

Serum total RANKL (sRANKL, free and unbound serum RANKL) and OPG levels were measured using commercially available kits based on sandwich enzyme-linked immunoassay (ELISA) method (Biovendor, Candler, NC 28715, USA). Reference range of OPG has been given as 1.8-6.4 pmol/L in the kit catalogue; whereas, it has not been mentioned for RANKL. The intra- and inter-assay CV (%) were 3.5 and 5.8 for OPG and 8.7 and 9.19 for RANKL, respectively. Limit of detection for RANKL was 0.2 pmol/L and that of OPG was 0.13 pmol/L.

**Measurement of BMD**

We have used BMD values of 29 MS patients which have been measured as a routine parameter. The BMD measurements of the other patients were not available. Also, BMD values of all control subjects were measured.

Bone mineral density measurements for the lumbar spine and femur were obtained by dual energy X-ray absorptiometry (DXA) using Hologic QDR 4500C. The CV (%) for the neck of femur and lumbar spine were 1.23 and 1.07%, respectively.

The z and t score calculations were done within the software used for DXA scans and obtained from the clinical reports. Patients were classified as normal with a BMD t score greater than −1.0, as osteoporotic with a BMD t score less than or equal to −1.0, but greater than −2.5 defines osteopenia, whereas t score less than or equal to −2.5 defines osteoporosis.

**Statistical Analysis**

All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, Version 16.0). The descriptive variables were defined as mean value ± standard deviation (SD). Statistical differences between the groups were evaluated using a χ² test, independent T-test and Mann Whitney U-test. The correlations between variables were performed by Pearson’s Correlation test for nominal data and Spearman Correlation analysis was performed for the relationship between ordinal data. Differences were considered significant at a probability level of p<0.05.

**Results**

Demographic characteristics of the patients and the controls are shown in Table 1. There were no significant differences between the groups in terms of age, gender and body mass index (BMI). BMI is a parameter which is known to effect bone turnover [23].

The biochemical findings are presented in Table 2. Serum OPG (p<0.01), RANKL (p<0.01), bALP (p<0.05), PTH (p<0.01) and Ca (p<0.01) levels of the patients were significantly higher than those of the controls (Figure 1). There were no significant differences between osteocalcin and DPD levels of the groups. Also, the lumbar spine (L1–L4) and femur neck BMD, t and z scores of MS patients were slightly but not significantly lower than those of the controls (Table 3).

There was a statistically significant positive correlation between EDSS and disease duration (r = 0.394, p<0.01) and between EDSS and attack number (r = 0.418, p<0.01) and a statistically significant negative correlation between EDSS and bALP levels (r = -0.346, p<0.05) in the MS patients.

There was a statistically significant positive correlation between RANKL and PTH levels (r = 0.357, p<0.05) and a statistically significant negative correlation between RANKL levels and neck BMD (r = -0.412, p<0.05). A statistically significant positive correlation between DPD levels and disease duration was found (r = 0.298, p<0.05). There were no correlations between any of the biochemical markers and BMD in the controls.
Table 1. Demographic characteristics of all patients and controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>MS patients (n=46)</th>
<th>Controls (n=24)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>33.48 ± 9.57 (ranges from 20 to 53)</td>
<td>33.04 ± 7.97 (ranges from 21 to 52)</td>
<td>0.850</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>16/30</td>
<td>10/14</td>
<td>0.572</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.70 ± 4.22</td>
<td>25.04 ± 3.95</td>
<td>0.538</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>28.30 ± 8.08 (ranges from 15 to 46)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>5.27 ± 4.07 (ranges from 1 to 16)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>EDSS score</td>
<td>2.54 ± 1.49 (ranges from 0.5 to 6.0)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Data are presented as mean values ± SD (except gender). MS; multiple sclerosis, BMI; body mass index, EDSS; Expanded Disability Status Scale, SD; standard deviation

Table 2. Biochemical findings of the patients and the controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>MS patients (n=46)</th>
<th>Controls (n=24)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANKL (pmol/L)</td>
<td>673.75 ± 221.07</td>
<td>515.33 ± 221.10</td>
<td>0.007</td>
</tr>
<tr>
<td>OPG (pmol/L)</td>
<td>2.70 ± 1.09</td>
<td>2.04 ± 0.70</td>
<td>0.003</td>
</tr>
<tr>
<td>RANKL/OPG</td>
<td>283.64 ± 138.05</td>
<td>287.88 ± 172.73</td>
<td>0.889</td>
</tr>
<tr>
<td>bALP (µg/L)</td>
<td>11.98 ± 4.42</td>
<td>9.84 ± 3.05</td>
<td>0.022</td>
</tr>
<tr>
<td>Osteocalcin (ng/mL)</td>
<td>10.63 ± 8.00</td>
<td>8.08 ± 5.04</td>
<td>0.241</td>
</tr>
<tr>
<td>Intact PTH (pg/mL)</td>
<td>63.42 ± 37.70</td>
<td>36.51 ± 25.93</td>
<td>0.002</td>
</tr>
<tr>
<td>DPD (pmol/µmol urinary Creatinine)</td>
<td>11.62 ± 4.57</td>
<td>10.14 ± 3.49</td>
<td>0.186</td>
</tr>
<tr>
<td>Ca (mg/dL)</td>
<td>9.64 ± 0.39</td>
<td>9.39 ± 0.34</td>
<td>0.011</td>
</tr>
</tbody>
</table>

Data are presented as mean values ± SD. MS; multiple sclerosis, RANKL; receptor activator of NF-kappaB ligand, OPG; osteoprotegerin, bALP; bone alkaline phosphatase, PTH; parathyroid hormone, Ca; calcium, SD; standard deviation

Table 3. The BMD measures of 29 patients and controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>MS patients (n=29)</th>
<th>Controls (n=24)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>32.70 ± 8.12 (ranges from 22 to 50)</td>
<td>33.04 ± 7.97 (ranges from 21 to 52)</td>
<td>0.887</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>11/18</td>
<td>10/14</td>
<td>0.539</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.96 ± 4.78</td>
<td>25.04 ± 3.95</td>
<td>0.465</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>27.63 ± 7.97</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Disease duration</td>
<td>5.30 ± 4.00</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>EDSS levels</td>
<td>2.41 ± 1.55</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>L1–L4 (BMD g/m²)</td>
<td>0.96 ± 0.10</td>
<td>0.98 ± 0.14</td>
<td>0.717</td>
</tr>
<tr>
<td>L1–L4 (t score)</td>
<td>-0.88 ± 1.02</td>
<td>-0.82 ± 1.27</td>
<td>0.674</td>
</tr>
<tr>
<td>L1–L4 (z score)</td>
<td>-0.63 ± 1.12</td>
<td>-0.69 ± 1.25</td>
<td>0.941</td>
</tr>
<tr>
<td>Neck of femur (BMD g/m²)</td>
<td>0.86 ± 0.12</td>
<td>0.92 ± 0.13</td>
<td>0.132</td>
</tr>
<tr>
<td>Neck of femur (t score)</td>
<td>-0.58 ± 1.12</td>
<td>-0.23 ± 1.15</td>
<td>0.177</td>
</tr>
<tr>
<td>Neck of femur (z score)</td>
<td>-0.96 ± 1.12</td>
<td>0.28 ± 1.21</td>
<td>0.265</td>
</tr>
</tbody>
</table>

Data are presented as mean values ± SD (except gender). BMD; bone mineral density, MS; multiple sclerosis, BMI; body mass index, EDSS; Expanded Disability Status Scale, L1–L4; lumbar spine, SD; standard deviation
Discussion

Elevated levels of RANKL and OPG in MS patients found in this study are consistent with the findings of our previous study [19]. This finding suggests that osteoclastogenetic effect of RANKL was compensated by elevated level of OPG in these patients. To the best of our knowledge, correlation between OPG and RANKL levels and BMD in MS patients was not investigated previously.

Receptor activator of nuclear factor kappaB ligand is synthesized at highest levels in bone and bone marrow, as well as in lymphoid tissues [9, 11, 12]. Pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 or IL-11 and PTH induce this synthesis [9, 11-14]. Elevated RANKL expression by T cells, as well as by osteoblasts play a role in bone loss in inflammatory diseases [13, 16-18]. Indeed, many reports have suggested that the RANKL/OPG ratio is a major determinant of bone mass [11, 13]. Therefore, it can be argued that significantly increased serum RANKL levels of MS patients induce osteoclastogenesis which can result in bone loss. However, lumbar spine and femur neck BMD of our patients were not changed in spite of increased levels of RANKL, a finding which shows the compensatory effect of OPG. It has been reported that osteoclastogenesis is under negative regulation of OPG, which functions as a decoy receptor for RANKL [9, 11-14]. By this way, OPG attenuates excessive RANKL signaling. Thus, OPG is regarded as a safeguard against excessive RANKL effects. This finding is in accordance with the findings of other investigators [15]. The seeming paradox of increased serum levels of OPG in patients with active osteoporosis has been interpreted as an incomplete regulatory mechanism to counteract disease progression [12]. Since pro-inflammatory cytokines are known to up-regulate OPG mRNA levels [9, 11-14], another possible mechanism of increased OPG levels can be explained by elevated serum level of pro-inflammatory cytokines in MS patients.

In addition, enhanced OPG level may be due to the binding of OPG on RANKL, which subsequently reducing OPG clearance [24].

Osteoprotegerin has been reported to block osteoclastogenesis stimulated by many hormones and cytokines, including PTH [14]. It has been shown that OPG blocks PTH induced osteoclastogenesis [25] and also prevents PTH induced bone resorption in organ cultures [26]. Thus, it was suggested that most or all factors which stimulate osteoclastogenesis do so through a pathway which can ultimately be blocked by OPG [25]. Furthermore, OPG has been suggested to increase bone mass and density independently from reduced osteoclastogenesis which is consistent with the possibility that OPG may directly affect bone metabolism beyond its known role as decoy receptor for RANKL [27].

Parathyroid hormone levels of our patients were higher than that of the controls but there was no significant difference between BMD values of the groups. We believe that this is also due to increased levels of OPG in MS patients. Some studies have shown that after PTH injection, RANKL expression is increased by osteoblasts [28], leading to activation of existing osteoclasts and release by them of a factor(s) that stimulates new bone formation [29].

Serum bALP levels of our patients were significantly increased; whereas, serum osteocalcin and urinary DPD levels were not significantly changed compared to those of controls. Since osteoclastic bone resorption normally initiates the bone turnover cycle, which is followed by osteoblastic bone formation [29, 30], increased serum bALP levels in our patients suggest deregulated bone turnover. In addition, the levels of bone formation and degradation markers are increased in disease states associated with bone loss [31]. Therefore, when the activation frequency is increased, the bone formation rate also increases. As a result, these provide an explanation for the increase in bALP levels in MS patients. Also, Grundt et al. [27] showed that OPG directly increased ALP activity in human osteoblastic cells. Thus, increased levels of OPG in our patients may result in increased activity. Although both bALP and osteocalcin are bone formation markers, they reflect different steps in the differentiation process of the osteoblastic process [32]. It has been reported that osteocalcin is less consistently raised in active disease compared with other formation markers such as ALP [33]. Also, a longer half-life of bALP in the circulation was thought to explain the discrepancy between markers [34].

Serum Ca levels of both groups were within reference ranges. However, Ca levels of our patients were significantly higher than that of control group, a finding which might be due to a compensatory mechanism against osteoporosis.

Although both OPG and RANKL levels were increased in our patients, RANKL/OPG ratio was not significantly
different from control group. RANKL/OPG ratio was reported to be decisive for clinical interpretation of bone mass findings [11, 13]. Thus, unchanged RANKL/OPG ratio of our patients provides another explanation for the lack of difference between BMD of the patients and the controls.

As it has been stated above, we have found no significant change in BMD levels of our patients. This could partly be explained by that all patients enrolled in our study were in relapsing remitting and all of them in remission period. Also, none of them were experiencing progression or developed new symptoms within six months prior to the onset of the study. Weinstock-Guttman et al. [4] have found that the lumbar and femur BMD were not statistically different between the relapsing remitting, secondary progressive and primary progressive groups, but there was a trend towards lower scores in the secondary progressive and the primary progressive groups compared to the relapsing remitting MS, a finding which supports our results.

In addition, the disease duration itself was reported to be an independent factor to affect BMD in MS patients [6]. Disease duration was about 5.3 years in our patients, a time span which is quite shorter compared to that of other studies [4, 5, 7].

Expanded Disability Status Scale was reported to be an important factor associated with low BMD [4, 5, 7]. It has been shown that mean EDSS score (6.79 ± 1.6) of the osteoporotic group was significantly higher than the EDSS score of the group with normal BMD scores (4.49 ± 2.4) and the group of osteopenic patients (5.79 ± 1.6) [4]. The mean EDSS score of our patients with BMD measures was 2.41 ± 1.55. This value is lower than the findings of the above investigators. Therefore, we can suggest that the lower EDSS score found in our patients did not result in a significant change in BMD levels [4, 7].

We have found a statistically significant negative correlation between RANKL levels and neck BMD (r = -0.412, p<0.05). Except this, there were no correlations between any of the biochemical markers we have measured and BMD in MS patients and in controls. Tuzun et al. [6] have found that there was no significant correlation between BMD and osteocalcin, PTH and urinary DPD levels. These findings are in agreement with our findings.

On the other hand, Stejskal et al. [35] have demonstrated that OPG concentrations were varied inversely with bone density values (correlation coefficient -0.31), a finding which is not in agreement with ours. The underlying mechanism of this inconsistency is not known.

In conclusion, our findings show that increased levels of RANKL, which is associated with osteoclastogenesis, is compensated by increased levels of OPG, a mechanism which seems to prevent a change in BMD of MS patients. Thus, evaluating OPG and RANKL levels in these patients may be used as specific clinical tests and may be helpful in defining the appropriate therapeutic intervention. Also, further studies involving the primary progressive and secondary progressive MS patients may provide additional information regarding the biochemical mechanism of MS disease.

**Ethical Considerations**

The study protocol was approved by the Ethics Committee of Meram Medical School, University of Selcuk, Konya, Turkey (Date: 27 February 2007, number: 280-1255). All subjects were informed of the details of the study and the written consent of each subject was received.

**Acknowledgments**

This research was supported by Grant 08401097 from University of Selcuk, Scientific Research Projects Department (BAP), Konya-Turkey. The study was presented as an oral presentation at XXI National Biochemistry Congress, November 28-31, 2009, Istanbul, Turkey.

**Conflict of Interest**

The authors declare no conflict of interest.

**References**


